Related Experiment Videos
A method for evaluation of brain tumor growth using implantable diffusion chambers
Abstract:
Major drawbacks associated with in vitro assays for sensitivity of brain tumors to specific chemotherapeutic drugs include uncertainty of end-point validity, the need for large tissue samples, and cost. Furthermore, these assays do not address the question of conversion of the drug to active moeities by metabolic pathways in the host or alteration of drug activity by binding to plasma protein. We propose to develop a technique for growth and quantitation of tumor cells in small-pore diffusion chambers that contain the tumor cells and protect them from the immune system of the immunologically unrelated host. These chambers, fabricated from acrylic rings and membranes of 0.22 microns pore size, are sterilized, filled with a precisely quantitated inoculum of tumor cells, and implanted in the peritoneal cavity of rats. Replication of the cells is determined by enzymatic digestion of the supporting matrix of the cells within the chamber and counting the single cell suspension with a hemocytometer or automated cell counter. Precise comparison can thus be made between different drugs regarding their effect on cell growth in the host. This assay can be performed with the basic equipment and personnel available in most cell culture laboratories and requires a small number of tumor cells. Mass production of the diffusion chambers may make the assay less costly and faster than assays that do not involve exposure of tumor to drug in a living host. In addition, the assay should permit screening of new chemotherapeutic agents against human tumors under physiologic conditions.
Insights
This study introduces a novel diffusion chamber assay for evaluating brain tumor chemotherapy sensitivity. The method offers a more accurate and cost-effective approach for drug screening in a living host environment.
Area of Science:
- Oncology
- Pharmacology
- Biotechnology
Background:
- In vitro chemotherapy sensitivity assays for brain tumors face limitations including endpoint validity issues, large tissue sample requirements, and high costs.
- Existing assays do not account for in vivo drug metabolism or plasma protein binding, impacting therapeutic efficacy.
- There is a need for a more reliable and physiologically relevant method to assess drug sensitivity in brain tumors.
Purpose of the Study:
- To develop and validate a diffusion chamber-based assay for quantifying brain tumor cell growth and chemosensitivity.
- To provide a cost-effective and efficient method for screening chemotherapeutic agents against brain tumors under in vivo conditions.
- To overcome the limitations of traditional in vitro assays by incorporating host physiological factors.
Main Methods:
- Utilizing small-pore (0.22 micron) diffusion chambers to culture and protect tumor cells from host immune responses.
- Implanting chambers containing quantified tumor cell inoculums into the peritoneal cavity of rats.
- Quantifying tumor cell replication via enzymatic digestion and cell counting using hemocytometers or automated counters.
Main Results:
- The diffusion chamber assay allows for precise comparison of different chemotherapeutic drugs' effects on tumor cell growth in a host.
- The method requires minimal tumor cells and basic cell culture laboratory equipment.
- The assay enables the screening of novel chemotherapeutic agents against human tumors under physiological conditions.
Conclusions:
- The proposed diffusion chamber assay offers a promising alternative to conventional in vitro methods for brain tumor drug sensitivity testing.
- This technique addresses key limitations of existing assays, providing more accurate and relevant data for therapeutic decisions.
- The assay has the potential to be cost-effective and faster, facilitating the development of new cancer therapies.